Table 3 Baseline characteristics at start of teriflunomide 14 mg (core and extension period; safety population)
From: Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
Treatment naive (n = 1018) | Previously treated with another DMT (n = 163) | Recently treated with another DMT (n = 158) | Overall Population (N = 1696)a | |
|---|---|---|---|---|
Age, mean (SD) years | 38.64 (9.06) | 37.82 (8.24) | 38.97 (9.62) | 38.68 (9.12) |
Female gender, n (%) | 718 (70.5) | 125 (76.7) | 114 (72.2) | 1211 (71.4) |
White, n (%) | 918 (90.3)b | 154 (95.1)c | 154 (97.5) | 1536 (90.7)d |
Time since diagnosis of MS, mean (SD) years | 5.06 (5.44)b | 7.95 (5.38) | 6.18 (6.04) | 5.80 (5.60)e |
Time since first symptoms of MS, mean (SD) years | 8.20 (6.71)b | 10.72 (6.69) | 9.39 (7.19) | 8.90 (6.87)e |
Number of relapses within past year, mean (SD) | 1.00 (0.82)f | 1.22 (0.85)g | 0.90 (0.88)h | 0.87 (0.84)i |
Baseline EDSS score | ||||
Mean (SD) | 2.59 (1.43) | 2.74 (1.40) | 2.49 (1.38) | 2.58 (1.43) |
Median (min, max) | 2.50 (0.0, 8.0) | 2.50 (0.0, 6.5) | 2.00 (0.0, 6.5) | 2.50 (0.0, 8.0) |
Last prior DMT,j,k n (%) | ||||
Fingolimod | 2 (1.8) | 3 (1.8) | 0 | 5 (0.6) |
GA | 36 (33.0) | 58 (35.6) | 27 (17.1) | 121 (15.4) |
IFNBl | 1 (0.9) | 0 | 2 (1.3) | 3 (0.4) |
IFNB-1a | 39 (35.8) | 68 (41.7) | 110 (69.6) | 217 (27.6) |
IFNB-1b | 31 (28.4) | 31 (19.0) | 19 (12.0) | 81 (10.3) |
Natalizumab | 0 | 3 (1.8) | 0 | 3 (0.4) |
Teriflunomide 7 mg | 0 | 0 | 0 | 357 (45.4) |